Your browser doesn't support javascript.
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
Ujjani, Chaitra; Shadman, Mazyar; Lynch, Ryan C; Tu, Brian; Stevenson, Philip A; Grainger, Caitlin; Zhu, Haiying; Hill, Joshua A; Huang, Meei-Li; Nielsen, Leslie; Poh, Christina; Sorensen, Tyler; Gopal, Ajay K; Warren, Edus H; Till, Brian G; Lee, Sydney; Gausman, Daria; Smith, Stephen D; Gooley, Ted; Greninger, Alex.
  • Ujjani C; University of Washington, Seattle, Washington, USA.
  • Shadman M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Lynch RC; University of Washington, Seattle, Washington, USA.
  • Tu B; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Stevenson PA; University of Washington, Seattle, Washington, USA.
  • Grainger C; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Zhu H; University of Washington, Seattle, Washington, USA.
  • Hill JA; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Huang ML; University of Washington, Seattle, Washington, USA.
  • Nielsen L; University of Washington, Seattle, Washington, USA.
  • Poh C; University of Washington, Seattle, Washington, USA.
  • Sorensen T; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Gopal AK; University of Washington, Seattle, Washington, USA.
  • Warren EH; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Till BG; University of Washington, Seattle, Washington, USA.
  • Lee S; University of Washington, Seattle, Washington, USA.
  • Gausman D; University of Washington, Seattle, Washington, USA.
  • Smith SD; University of Washington, Seattle, Washington, USA.
  • Gooley T; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Greninger A; University of Washington, Seattle, Washington, USA.
Br J Haematol ; 197(3): 306-309, 2022 05.
Article in English | MEDLINE | ID: covidwho-1700211
ABSTRACT
Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Br J Haematol Year: 2022 Document Type: Article Affiliation country: Bjh.18088

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Br J Haematol Year: 2022 Document Type: Article Affiliation country: Bjh.18088